Market Intelligence, Clinical Progress, and High-Purity Reagents for Wnt-Driven Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RSPO2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RSPO2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View RSPO2 Products |
| Gene Delivery | RSPO2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View RSPO2 Products |
| Benchmark Ab | Anti-RSPO2 Recombinant Antibody Recombinant positive control. |
View RSPO2 Products |
| Validator | RSPO2 siRNA Set For knockdown verification. |
View RSPO2 Products |
| Related Target A | LGR5 Primary functional receptor for RSPO ligands; critical for Wnt signal potentiation. |
View LGR5 Products |
| Related Target B | ZNRF3 E3 ubiquitin ligase cleared by RSPO2; target for receptor stabilization assays. |
View ZNRF3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily off-target screening (RSPO1/3/4) | Homolog panel proteins strictly verified by mass spectrometry and high purity (>95%) |
| Native post-translational modifications | HEK293 Host Expression ensuring native mammalian glycosylation patterns |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live RSPO2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RSPO2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted bispecifics and decoy receptors. As first-generation therapies reach the clinic, the next wave of R&D is targeting RSPO2-fusion positive solid tumors, particularly in colorectal and gastric cancers where RSPO2/3 gene fusions drive hyperactivation of the Wnt pathway.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | OncoMed, AbbVie | Colorectal Cancer, Gastric Cancer | Ligand-blocking assays (Need high-purity, native-conformation RSPO2 ECD-Fc) |
| Bispecific Antibody | Biotech Developers | Wnt-driven Solid Tumors | Dual-targeting validation (Need cross-reactive RSPO2 & LGR5/ZNRF3 partner proteins) |
| Decoy Receptor | Academic Institutes | Fibrotic Diseases, Oncological Malignancies | Binding kinetics & competition assays (Need sequence-verified receptor extracellular domains) |